אמריל 1 מג ישראל - עברית - Ministry of Health

אמריל 1 מג

sanofi israel ltd - glimepiride - טבליה - glimepiride 1 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

אמריל 2 מג ישראל - עברית - Ministry of Health

אמריל 2 מג

sanofi israel ltd - glimepiride - טבליה - glimepiride 2 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

אמריל 3 מג ישראל - עברית - Ministry of Health

אמריל 3 מג

sanofi israel ltd - glimepiride - טבליה - glimepiride 3 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

אמריל 4 מג ישראל - עברית - Ministry of Health

אמריל 4 מג

sanofi israel ltd - glimepiride - טבליה - glimepiride 4 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

קלקסן ישראל - עברית - Ministry of Health

קלקסן

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

קלקסן ישראל - עברית - Ministry of Health

קלקסן

sanofi - aventis israel ltd - enoxaparin sodium 100 mg/ml - solution for injection - enoxaparin - treatment of acute st-segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible or not for subsequent coronary angioplasty.

פלויקס 75 מג ישראל - עברית - Ministry of Health

פלויקס 75 מג

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

פלויקס 300 מ"ג ישראל - עברית - Ministry of Health

פלויקס 300 מ"ג

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

פרלסיט ישראל - עברית - Ministry of Health

פרלסיט

sanofi israel ltd - iron as iron iii sodium ferric glugonate compl. - solution for injection - iron as iron iii sodium ferric glugonate compl. 62.5 mg / 5 ml - various combinations - various combinations - severe iron deficiency states only when oral administration has been found impossible in cases of gastrointestinal malabsorption which rules out oral iron therapy patients treated by dialysis getting erythropoietin.

מולטאק ישראל - עברית - Ministry of Health

מולטאק

sanofi israel ltd - dronedarone - טבליות מצופות פילם - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.